Mono- and dinuclear (η6-arene) ruthenium(II) benzaldehyde thiosemicarbazone complexes: Synthesis, characterization and cytotoxicity

被引：62
作者：
Stringer, Tameryn [1 ]
Therrien, Bruno [2 ]
Hendricks, Denver T. [3 ]
Guzgay, Hajira [3 ]
Smith, Gregory S. [1 ]
机构：
[1] Univ Cape Town, Dept Chem, ZA-7701 Cape Town, South Africa
[2] Univ Neuchatel, Inst Chim, CH-2000 Neuchatel, Switzerland
[3] Univ Cape Town, Div Med Biochem, ZA-7701 Cape Town, South Africa
来源：
INORGANIC CHEMISTRY COMMUNICATIONS | 2011年 / 14卷 / 06期
基金：
新加坡国家研究基金会;
关键词：
Bioorganometallic chemistry; Arene ruthenium(II); Thiosemicarbazones; Anticancer drugs; ARENE COMPLEXES; IN-VITRO; ANTICANCER DRUGS; DNA-BINDING; NAMI-A; PLATINUM; RESISTANCE; CANCER; INHIBITION; STRATEGIES;
D O I：
10.1016/j.inoche.2011.03.041
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
A series of mono- and dinuclear (eta(6)-arene) ruthenium(II) complexes were prepared by reaction of thiosemicarbazone ligands derived from benzaldehyde and ruthenium(II) precursors of the general formula [Ru(eta(6)-arene)(mu-Cl)Cl](2), where arene = p-(PrC6H4Me)-Pr-i or C6H5C3H6COOH. These complexes were characterized by NMR and IR spectroscopy, ESI-mass spectrometry and elemental analysis. The molecular structure of the mononuclear p-cymene complex was determined by X-ray diffraction analysis, revealing a pseudo-tetrahedral piano stool conformation and a bidentate N,S coordination mode of the thiosemicarbazone ligand. The complexes and ligands were evaluated for their in vitro cytotoxicity against the WHCO1 oesophageal cancer cell line. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码：956 / 960
页数：5
相关论文
共 48 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]   In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].
Aird, RE ;
Cummings, J ;
Ritchie, AA ;
Muir, M ;
Morris, RE ;
Chen, H ;
Sadler, PJ ;
Jodrell, DI .
BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657
[3]   Development of organometallic (organo-transition metal) pharmaceuticals [J].
Allardyce, CS ;
Dorcier, A ;
Scolaro, C ;
Dyson, PJ .
APPLIED ORGANOMETALLIC CHEMISTRY, 2005, 19 (01) :1-10
[4]   Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].
Ang, Wee Han ;
Dyson, Paul J. .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018
[5]   The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation [J].
Bacac, M ;
Hotze, ACG ;
van der Schilden, K ;
Haasnoot, JG ;
Pacor, S ;
Alessio, E ;
Sava, G ;
Reedijk, J .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2004, 98 (02) :402-412
[6]   Unusual coordination mode of thiosemicarbazone ligand. Synthesis, structure, and redox properties of some ruthenium and osmium complexes [J].
Basuli, F ;
Ruf, M ;
Pierpont, CG ;
Bhattacharya, S .
INORGANIC CHEMISTRY, 1998, 37 (23) :6113-6116
[7]   Organometallic ruthenium complexes with thiosemicarbazone ligands: Synthesis, structure and cytotoxicity of [(η6-p-cymene)Ru(NS)Cl]+ (NS=9-anthraldehyde thiosemicarbazones) [J].
Beckford, Floyd A. ;
Leblanc, Gabriel ;
Thessing, Jeffrey ;
Shaloski, Michael, Jr. ;
Frost, Brian J. ;
Li, Liya ;
Seeram, Navindra P. .
INORGANIC CHEMISTRY COMMUNICATIONS, 2009, 12 (11) :1094-1098
[8]   ARENE RUTHENIUM(II) COMPLEXES FORMED BY DEHYDROGENATION OF CYCLOHEXADIENES WITH RUTHENIUM(III) TRICHLORIDE [J].
BENNETT, MA ;
SMITH, AK .
JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1974, (02) :233-241
[9]   The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes [J].
Beraldo, H ;
Gambino, D .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (01) :31-39
[10]   CONTROLLING PLATINUM, RUTHENIUM, AND OSMIUM REACTIVITY FOR ANTICANCER DRUG DESIGN [J].
Bruijnincx, Pieter C. A. ;
Sadler, Peter J. .
ADVANCES IN INORGANIC CHEMISTRY, VOL 61: METAL ION CONTROLLED REACTIVITY, 2009, 61 :1-62
12345